A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
By Takaaki Sasaki, J. Koivunen, Atsuko Ogino, M. Yanagita, S. Nikiforow, Wei Zheng, C. Lathan, J. P. Marcoux, Jinyan Du, K. Okuda and 16 more. Cancer Research, 2011
620 citations recorded by the source corpus.
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we report two mechanisms of ALK TKI resistance identified from, a crizotinib treated non-small cell lung cancer (NSCLC) patient and in a cell line generated from the resistant tumor (DFCI076), and from studying a resistant version of the ALK TKI (TAE684) sensitive H3122 cell line. The crizotinib resistant DFCI076 cell line, harboured a unique L1152R ALK secondary mutation, and was also resistant to the structurally unrelated ALK TKI TAE684. Although the DFCI076 cell line was still partially dependent on ALK for survival, it also contained concurrent co-activation of epidermal growth factor receptor (EGFR) signalling. In contrast, the TAE684 resistant (TR3) H3122 cell line did not contain an ALK secondary mutation but instead harboured co-activation of EGFR signalling. Dual inhibition of both ALK and EGFR was the most effective therapeutic strategy for the DFCI076 and H3122 TR3 cell lines. We further identified a subset (3/50; 6%) of treatment naïve NSCLC patients with ALK rearrangements that also had concurrent EGFR activating mutations. Our studies identify resistance mechanisms to ALK TKIs mediated by both ALK and by a bypass signalling pathway mediated by EGFR. These mechanisms can occur independently, or in the same cancer, suggesting that the combination of both ALK and EGFR inhibitors may represent an effective therapy for these subsets of NSCLC patients.
Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/bc8e7341aa3f3ff8e5fcbc0bee20843fd570aaf3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “Inhibition of EGFR resensitizes the resistant cancers to their respective TKI (Katayama et al., 2012; McDermott et al., 2010; Qi et al., 2011; Sasaki et al., 2011).”
- Mechanisms of receptor tyrosine kinase activation in cancer (2018, neutral): “through either acquired genomic alterations [186, 187] or activation of critical signaling pathways [188–190].”
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer (2012, positive): “However, when separate or second drivers occur – drug combinations or broader based treatments such as cytotoxic chemotherapies may be required (13, 45).”